EGFR and head and neck squamous cell carcinoma: EGF stimulation increased by threefold the expression of endogenous miR‐9 (Fig 2B), while inhibition of EGFR with gefitinib, a small‐molecule inhibitor, or Cetuximab (CTX), a monoclonal antibody approved for the treatment of HNSCC patients in combination with RT (Santuray et al,2018), decreased the activity of miR‐9 promoter and reduced the expression of endogenous miR‐9, in both control and anti‐miR‐9 FaDu cells (Fig 2C–F).